References
- RaiszLPathogenesis of osteoporosis: concepts, conflicts, and prospectsJ Clin Invest2005115123318332516322775
- EttingerBBlackDMNevittMCContribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research GroupJ Bone Miner Res1992744494561535172
- CauleyJAThompsonDEEnsrudKCScottJCBlackDRisk of mortality following clinical fracturesOsteoporos Int200011755656111069188
- CummingsSRMeltonLJEpidemiology and outcomes of osteoporotic fracturesLancet200235993191761176712049882
- EriksenEFCellular mechanisms of bone remodelingRev Endocr Metab Disord201011421922721188536
- FleischHBisphosphonates in Bone Disease: From the Laboratory to the Patient4th edSan DiegoAcademic Press2000
- TanakaMMoriHShimizuKPharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosisNihon Yakurigaku Zasshi20091343149157 Japanese19749488
- SorberaLACapstanerJLeesonPAMinodronic acidDrugs Future200227935941
- DunfordJEThompsonKCoxonFPStructure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonatesJ Pharmacol Exp Ther2001296223524211160603
- TanishimaSKishimotoYFukataSMizumuraHHaginoHTeshimaRMinodronic acid influences receptor activator of nuclear factor kappaB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritisMod Rheumatol200717319820517564774
- KuboTShimoseSMatsuoTFujimoriJOchiMMinodronate for the treatment of osteoporosisDrugs Today (Barc)2010461333720200694
- HaginoHNishizawaYSoneTA double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosisBone20094461078108419264155
- MatsumotoTHaginoHShirakiMEffect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind studyOsteoporos Int20092081429143719101754
- ItoMSoneTFukunagaMEffect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosisJ Bone Miner Metab201028333434119937358
- OkazakiRHaginoHItoMEfficacy and safety of monthly oral minodronate in patients with involutional osteoporosisOsteoporos Int20122361737174521932114
- RossPDFujiwaraSHuangCVertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the USInt J Epidemiol1995246117111778824859
- MoriHNisshizawaYTaketaniYA randomized controlled trial with ONO-5290 in Japanese patients with postmenopousal osteoporosis [abstract]J Bone Miner Res200217Suppl 1S471
- YamaneIHaginoHOkanoTEnokidaMYamasakiDTeshimaREffect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritisArthritis Rheum20034861732174112794842
- MoriHKayasugaRTanakaMInhibitory effect of minodronic acid on bone resorption in vitro and in vivo – comparison with risedronate and alendronateClin Pharmacol Ther200818S19S32
- StrampelWEmkeyRCivitelliRSafety considerations with bisphosphonates for the treatment of osteoporosisDrug Saf200730975576317722968
- SchnitzerTBoneHGCrepaldiGTherapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupAging (Milano)200012111210746426
- DielIJBergnerRGrötzKAAdverse effects of bisphosphonates: current issuesJ Support Oncol200751047548218240669